Pernix Therapeutics to Report First Quarter 2013 Financial Results on May 10, 2013

  Pernix Therapeutics to Report First Quarter 2013 Financial Results on May
  10, 2013

    Management to Host a Conference Call on May 10, 2013 at 9:00 a.m. EST

Business Wire

THE WOODLANDS, Texas -- May 3, 2013

Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical
company, today announced that it will release its first quarter 2013 financial
results before the U.S. stock market opens on Friday, May 10, 2013 and has
scheduled a conference call at 9:00 a.m. EST that day to discuss the financial

The conference call will feature remarks by Cooper Collins, President and
Chief Executive Officer, and Tracy Clifford, Vice President of Accounting and
Corporate Controller. To participate in the conference call, please dial (877)
312-8783 (domestic) or (408) 940-3874 (international). Participants can
reference the passcode 50828084. Please dial in approximately 5 minutes prior
to the call.

The conference call will also be available via a live listen-only webcast and
can be accessed through the Investor Relations section of the Company’s
website Please allow extra time prior to the call to visit
the Company’s website and download any software that may be needed to listen
to the webcast.

A replay of the conference call will be available through May 17, 2013, at
(855) 859-2056 domestic and (404) 537-3406 international. The passcode for the
replay is 50828084. An online archive of the webcast will be available on the
Company’s website for 30 days following the call.

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on
the sales, marketing, manufacturing and development of branded, generic and
OTC pharmaceutical products. The Company manages a portfolio of branded
products, including the recently acquired Hawthorn Pharmaceuticals’ product
line. The Company’s branded products for the pediatrics market include CEDAX®,
an antibiotic for middle ear infections, NATROBA™, a topical treatment for
head lice marketed under an exclusive co-promotion agreement with ParaPRO,
LLC, and a family of treatments for cough and cold (ZUTRIPRO®, BROVEX®, ALDEX®
and PEDIATEX®). The Company’s branded products for gastroenterology include
OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer
disease, and REZYST™, a probiotic blend to promote dietary management. The
Company also markets the branded product, SILENOR®, for the treatment of
insomnia. The Company promotes its branded pediatric and gastroenterology
products through its sales force. Pernix markets its generic products through
its wholly-owned subsidiaries, Cypress Pharmaceutical and Macoven
Pharmaceuticals. The Company’s wholly-owned subsidiary, Pernix Manufacturing,
manufactures and packages products for the pharmaceutical industry in a wide
range of dosage-forms. Dr. Cocoa, a chocolate flavored cough and cold product,
is in development for the U.S. OTC markets.

Additional information about Pernix is available on the Company’s website
located at


Pernix Therapeutics Holdings, Inc.
Joseph T. Schepers, (800) 793-2145 ext. 3002
Director, Investor Relations
Press spacebar to pause and continue. Press esc to stop.